• Explore /
  • Poster
  • / Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.

Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.

Abstract Video & Slides Poster

Authors

null

Joaquim Bellmunt

Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, MA

Joaquim Bellmunt , Thomas Powles , Se Hoon Park , Eric Voog , Begoña Pérez Valderrama , Howard Gurney , Anders Ullén , Yohann Loriot , Srikala S. Sridhar , Norihiko Tsuchiya , Cora N. Sternberg , Jeanny B. Aragon-Ching , Daniel P. Petrylak , Miguel A. Climent Duran , Karin Tyroller , Jason Hoffman , Natalia Jacob , Petros Grivas , Shilpa Gupta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02603432

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4566)

DOI

10.1200/JCO.2024.42.16_suppl.4566

Abstract #

4566

Poster Bd #

261

Abstract Disclosures

Similar Posters

First Author: Yohann Loriot

First Author: Masatoshi Eto

First Author: Norihiko Tsuchiya

First Author: Jeanny B. Aragon-Ching